DSIP · adverse-event profile · research use only
DSIP side effects: a clean record, from a small and old set of studies.
DSIP (delta sleep-inducing peptide) has one of the more reassuring — and one of the most honestly caveated — safety records in the research-peptide space. The anchor is a 1981 double-blind crossover study (Schneider-Helmert et al.) in six volunteers given 25 nmol/kg intravenously: the compound was reported as 'well tolerated' with 'no psychologic, physiologic, or biochemical side effects observed,' and — importantly — the EEG analysis showed no sedation of the classic pharmacologic kind. Later placebo-controlled sleep-lab work in chronic insomniacs (Schneider-Helmert 1987; Bes 1992) similarly reported no meaningful adverse-event burden, though the sleep benefit itself was modest and inconsistent. The single most important thing to understand is what the record is NOT: it is small (handfuls of subjects), old (largely 1980s–90s), mostly intravenous rather than the nasal route sold today, short in duration, and without modern long-term pharmacovigilance. DSIP is also an endogenous nonapeptide the body already makes, which frames — but does not by itself prove — the low-toxicity picture. DSIP is one of the compounds Titan actually stocks, as a nasal spray. This page reproduces published literature as a research reference — not a human-use protocol or medical advice.
The anchor finding: 'no side effects observed'
The most-cited human study is Schneider-Helmert et al. (1981), a double-blind crossover in six volunteers dosed at 25 nmol/kg by slow IV infusion. Subjects reported a feeling of sleep pressure and slept more, but the authors' explicit conclusion on tolerability was that the compound was 'well tolerated' with 'no psychologic, physiologic, or biochemical side effects observed.' That is a strong statement — but it comes from a six-person study, so read it as 'nothing showed up in a small careful look,' not as a large-scale safety clearance.
DSIP half-life →No classic sedation — it works differently from a sleeping pill
A recurring theme across the DSIP sleep literature is that its EEG signature does NOT look like a sedative-hypnotic. The 1981 analysis found the sleep increase was not accompanied by the classic pharmacologic sedation you would see from a benzodiazepine or Z-drug; the framing in the papers is that DSIP appears to 'sustain natural sleep functions' rather than force unconsciousness. Practically, that means the profile discussed in the studies lacks the next-day sedative hangover pattern associated with hypnotic drugs — though 'discussed in the studies' is doing real work in that sentence.
DSIP vs Selank →It's a peptide the body already makes
DSIP is an endogenous nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated by Monnier and Schoenenberger from the cerebral venous blood of sleeping rabbits — i.e. it is a naturally occurring signalling peptide, not a foreign xenobiotic drug. That biology is part of why the toxicity picture in the studies is benign, and it is a fair point to make. It is NOT, however, a guarantee of safety at any dose or route: an endogenous molecule delivered exogenously in non-physiologic amounts is still an intervention, and the human data does not span modern dosing patterns.
Research-use policy →Route matters: the studies were mostly IV, the product is nasal
Almost all the controlled human DSIP data used intravenous infusion, whereas the material sold in this space — including Titan's — is an intranasal spray. As with any nasal peptide, the mucosa is the tissue that reacts first, so local nasal or sinus irritation is the most plausible route-specific effect even though it isn't quantified in the IV literature. This is a genuine gap: the tolerability numbers you can cite are for a delivery route different from the one you'd actually use, so treat nasal-route tolerability as reasonable-by-analogy rather than directly demonstrated.
Nasal spray handling →The honest caveat: the data is thin, old and short
The most important sentence on this page is this one. DSIP's clean record rests on a small number of studies, most from the 1980s–90s, most in the low double-digits of subjects, most only days-to-weeks long, and none constituting modern long-term pharmacovigilance. There is no large modern safety database. So the correct read is: 'no adverse-event signal has emerged in the limited studies that exist,' which is meaningfully weaker than 'proven safe.' Absence of evidence of harm from a small old dataset is not the same as evidence of long-term safety.
Dosage reference →Why identity verification still matters
DSIP is a short linear nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu). Because it is small and unmodified, a truncated fragment or a mis-synthesised sequence can pass a bare HPLC purity number while being the wrong molecule — so identity is confirmed by mass spectrometry against the full expected sequence, not a purity percentage alone. With a compound whose whole appeal is a benign, endogenous-molecule profile, the real-world variable is sourcing: identity, purity and sterility. Titan supplies DSIP nasal spray with lot-matched, in-house release documentation (HPLC + ESI-MS) available on request.
DSIP nasal spray — $62.99 →The detail, in plain terms
The tolerability record, at a glance.
Points below are drawn from the published DSIP human literature (largely Swiss and Dutch sleep-lab studies from the 1980s–90s) and reproduced as a research reference. The dataset is small, old, mostly intravenous and short-duration, and lacks modern long-term pharmacovigilance; treat the profile as clean-in-the-studies-that-exist rather than proven safe.
- Anchor tolerability finding
- 'Well tolerated; no psychologic, physiologic, or biochemical side effects observed' — Schneider-Helmert et al. 1981, double-blind crossover, 6 volunteers, 25 nmol/kg IV.
- Sedation
- No classic pharmacologic sedation on EEG analysis; described as sustaining natural sleep rather than forcing it.
- Sleep benefit
- Modest and inconsistent in controlled insomnia studies (Bes 1992 called short-term benefit unlikely to be major); tolerability was still unremarkable.
- Nasal / sinus irritation
- Plausible for the intranasal route by analogy with other nasal peptides; not quantified in the IV literature.
- Molecule type
- Endogenous nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) the body already produces — frames, but does not prove, the benign picture.
- Delivery-route gap
- Controlled data is mostly intravenous; the product sold today is intranasal — route-specific tolerability is inferred, not directly demonstrated.
- Long-term safety
- Not established; no large modern dataset and no long-term pharmacovigilance.
- Identity check
- 9-mer sequence confirmed by MS; a truncated fragment can hide behind a purity % alone.
Questions researchers ask
Before you order.
- What are the side effects of DSIP?
- In the published human studies — mostly small Swiss and Dutch sleep-lab trials from the 1980s–90s — no meaningful adverse-event burden was reported, and the anchor 1981 study explicitly recorded 'no psychologic, physiologic, or biochemical side effects observed.' The most plausible route-specific effect for the nasal-spray form sold today is mild nasal or sinus irritation, by analogy with other nasal peptides. These are research observations reproduced as a reference, not medical advice.
- Is DSIP safe?
- The honest answer is 'clean in the studies we have, but the studies we have are few, old, mostly intravenous and short.' No adverse-event signal has emerged from the limited controlled literature, and DSIP is an endogenous peptide the body already makes — both reassuring. But there is no large modern safety database and no long-term pharmacovigilance, so this should be read as absence of a signal in a small dataset rather than proof of long-term safety.
- Does DSIP cause a sedative hangover or grogginess the next day?
- The distinctive point in the DSIP literature is that its EEG signature does not look like a classic sedative-hypnotic — the 1981 analysis found the sleep effect was not accompanied by classic pharmacologic sedation, and the papers frame it as sustaining natural sleep rather than forcing unconsciousness. That argues against the next-day hangover pattern seen with hypnotic drugs, but it is inferred from a small dataset and should not be treated as a guarantee.
- Is DSIP a natural peptide?
- Yes — DSIP is an endogenous nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) that the body produces; it was originally isolated from the cerebral venous blood of sleeping rabbits by Monnier and Schoenenberger. That it is a naturally occurring signalling molecule helps explain the benign toxicity picture in the studies, but delivering it exogenously in non-physiologic amounts is still an intervention, and 'natural' does not equal 'safe at any dose or route.'
- How is DSIP identity confirmed on a certificate?
- DSIP is a short linear nonapeptide, so a truncated fragment or a mis-synthesised sequence can pass a bare HPLC purity number while being the wrong molecule. Identity is therefore confirmed by mass spectrometry against the full expected sequence rather than by a purity percentage alone. Titan provides lot-matched, in-house release documentation (HPLC + ESI-MS identity) on request.
- Is DSIP approved for human use?
- No. DSIP has been studied in humans in small research settings but is not an FDA-approved drug in the United States. Titan Peptide Lab supplies DSIP nasal spray strictly as a research-use-only reagent for in-vitro laboratory work — not for human or animal consumption. The tolerability data here summarises published literature and is not medical or dosing advice.